Karuna Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative therapies for neuropsychiatric disorders. The company was founded in 2009 and is based in Boston, Massachusetts.
Karuna Therapeutics is dedicated to addressing the unmet medical needs of patients suffering from conditions such as schizophrenia and Alzheimer's disease. They aim to develop novel therapeutics that target specific receptors in the brain to modulate the activity of neurotransmitters and restore proper brain function.
One of their leading drug candidates is KarXT, which is being developed as a potential treatment for acute psychosis in patients with schizophrenia. KarXT combines xanomeline, a muscarinic agonist, and trospium, an FDA-approved muscarinic antagonist, to provide a selective and balanced approach to modulating neurotransmitter activity in the brain.
The company's drug development efforts are based on deep scientific research and understanding of the underlying neurobiology of these disorders. They employ a multidisciplinary approach, combining expertise in neuroscience, pharmacology, and clinical development to advance their pipeline of therapeutic candidates.
Karuna Therapeutics is committed to improving the lives of patients by advancing innovative therapies for neuropsychiatric disorders. Through their focus on developing targeted treatments that address the underlying causes of these conditions, they aim to make a significant impact on patient outcomes and contribute to the advancement of mental health care.